Page last updated: 2024-08-24

plerixafor and Injury, Myocardial Reperfusion

plerixafor has been researched along with Injury, Myocardial Reperfusion in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Limbourg, FP1
Asahi, M; Clarke, T; Hagiwara, N; Ii, M; Ito, A; Jujo, K; Kamide, C; Klyachko, E; Losordo, DW; Misener, S; Qin, G; Renault, MA; Roncalli, J; Sekiguchi, H; Tanaka, T; Thorne, T; Tongers, J; Tsurumi, Y1

Other Studies

2 other study(ies) available for plerixafor and Injury, Myocardial Reperfusion

ArticleYear
A quick fix?: Short-term CXC-chemokine receptor 4 inhibition redistributes proangiogenic bone marrow cells to ischemic myocardium in an endothelial nitric oxide synthase--dependent fashion.
    Circulation, 2013, Jan-01, Volume: 127, Issue:1

    Topics: Animals; Benzylamines; Cyclams; Female; Heterocyclic Compounds; Male; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Receptors, CXCR4

2013
CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism.
    Circulation, 2013, Jan-01, Volume: 127, Issue:1

    Topics: Animals; Benzylamines; Bone Marrow Transplantation; Cardiotonic Agents; Cyclams; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Receptors, CXCR4; Recovery of Function; Signal Transduction

2013